AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02787317
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin is used in patients undergoing percutaneous coronary intervention.
Trial: NCT00594620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01096979
Drug: LIPO-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT01096979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02111850
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5 % in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hour.
Trial: NCT02485821
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02485821
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01901172
Drug: RO5503781
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily for 5 days followed by 23 days rest per cycle
Trial: NCT01901172
Drug: RO5503781
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses Days 1 and 11
Trial: NCT03658473
Drug: 550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
Trial: NCT03658473
Drug: 550 mg naproxen + placebo + 20 mg rabeprazole
RxNorm normalized name: naproxen sodium 550 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 550 mg naproxen 2x daily + placebo of rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
Trial: NCT03658473
Drug: 550 mg naproxen + 300 mg rebamipide + placebo
RxNorm normalized name: naproxen sodium 550 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + placebo of rabeprazole 1x daily over 7 days.
Trial: NCT04732988
Drug: HSG4112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral administration
Trial: NCT04732988
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral administration
Trial: NCT01711749
Drug: Crestor®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation is rosuvastatin calcium tablets, 20mg, currently commercialized by AstraZeneca do Brasil Ltda., under the trademark Crestor®
Trial: NCT01711749
Drug: rosuvastatin calcium tablets
RxNorm normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Test formulation is rosuvastatin calcium tablets, 20 mg, produced by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda.
Trial: NCT02194023
Drug: Placebo: PCB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
Trial: NCT02194023
Drug: 0.03%NF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
Trial: NCT00648024
Drug: Agrylin® Capsules 1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg, single dose fasting
Trial: NCT01461941
Drug: E6005
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
Trial: NCT01461941
Drug: E6005 ointment (vehicle)
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
Trial: NCT01198834
Drug: Etodolac
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of up to two patches at the discretion of the investigator for up to 7 days.
Trial: NCT02843659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT01872845
Drug: Pravastatin 40mg
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin 40mg PO daily for 1year from the day of BES implantation
Trial: NCT01872845
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
Trial: NCT02960438
Drug: E6011
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous administration
Trial: NCT02960438
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous administration
Trial: NCT00517543
Drug: GW856553
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04815395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo orally
Trial: NCT01269450
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 200mg vaginal tablets
Trial: NCT01522950
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet daily
Trial: NCT03121014
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5mg/m\^2 on Day 1, 5 mg/m\^2 on Days 3, 6 and 11
Trial: NCT00412737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to oseltamivir capsule or suspension orally once daily for 12 weeks.
Trial: NCT00002829
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infused intravenously over 2 hours daily on Day -7 and -6.
Trial: NCT04039919
Drug: Placebo (PSL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be provided matching Padsevonil to maintain the blinding.
Trial: NCT01882179
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03728023
Drug: AZD4205
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days
Trial: NCT03728023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose in SAD and once daily for 14 days
Trial: NCT00312819
Drug: chemotherapy +/- disulfiram
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01083017
Drug: chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chlorthalidone 25mg/d vs. chlorthalidone 50mg/d
Trial: NCT01083017
Drug: standardized anti-hypertensive treatment
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan, amlodipine, chlorthalidone, +- spironolactone
Trial: NCT03135899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses, each 12 hours apart
Trial: NCT04227938
Drug: ALPN-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of ALPN-101 will be administered via intravenous infusion.
Trial: NCT03802617
Drug: MR13A9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT03802617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT02139618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03914118
Drug: Preoperative placebo + postoperative placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pre-operatively and placebo immediately post-operatively.
Trial: NCT00255151
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
Trial: NCT01699919
Drug: Intravenous lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.
Trial: NCT00500279
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04358133
Drug: NaCl 0,9%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive placebo NaCl 0.9% administered according to the same protocol as the experimental arm
Trial: NCT02555293
Drug: XIFAXAN® (Rifaximin)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02507440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
Trial: NCT03392740
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given a look-alike placebo medication once a day prior to starting an anthracycline chemotherapy regimen. They will be given a new placebo medication in a step-wise fashion over period of 1 to 3 weeks.
Trial: NCT03915496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as two tablets to be taken orally once daily for 12 weeks
Trial: NCT04441099
Drug: NBE-002
RxNorm normalized name: BENZOCAINE 20 g in 100 g ORAL GEL [NBE Anbesol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.
Trial: NCT01557842
Drug: Drug Treatment
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class I and III antiarrhythmic drug treatment.
Trial: NCT00743509
Drug: Cyclophosphamide and Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The dose of cyclophosphamide will start at 200 mg (4 tablets) per day on day 1 and will be taken for 7 days every other week of a 28 day cycle.~Subjects will take 12 mg (12 tablets) of sirolimus on day 1 of treatment as a loading dose followed by 4 mg (4 tablets) daily continuously
Trial: NCT02783430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single perfusion during 40 minutes at the beginning of the inclusion
Trial: NCT00512707
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone Gel 1%: Starting active dose 10 g/day. Increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
Trial: NCT03018171
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal
Trial: NCT02533284
Drug: bupevecaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US guided TAP using Bupevecaine 0.25 %
Trial: NCT03355209
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered twice a day (BID) in equally divided doses.
Trial: NCT03614494
Drug: Piroxicam 40 mg
RxNorm normalized name: piroxicam 40 MG
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Additional co-treatment
Trial: NCT03348748
Drug: Stereotactic Body Radiation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo lowest-dose of SBRT
Trial: NCT03348748
Drug: Stereotactic Body Radiation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo lowest- or higher-dose of SBRT
Trial: NCT03348748
Drug: Stereotactic Body Radiation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo highest-dose of SBRT
Trial: NCT01652729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule once daily
Trial: NCT03651726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets
Trial: NCT00799916
Drug: Resuscitation (Voluven)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resuscitation aimed at venous oxygen saturation higher than 70%
Trial: NCT00799916
Drug: Resuscitation (Saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resuscitation aimed at venous oxygen saturation higher than 70%
Trial: NCT01633294
Drug: Ampicillin + gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ampicillin 1 g every six hours and gentamicin 240 mg every day intravenously
Trial: NCT01120769
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT01120769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT01046630
Drug: AZD6765
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single infusion
Trial: NCT01046630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single infusion
Trial: NCT01567826
Drug: standard of care lipid therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.~Zocor, Lipitor \[any dose\] and Crestor \[less than 40mg\]
Trial: NCT01567826
Drug: Aggressive lipid therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
Trial: NCT01349101
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days on days +3 and +4.
Trial: NCT02839668
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of 1 g acetaminophen for postoperative analgesia
Trial: NCT01969474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01014962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral once daily for 5 days
Trial: NCT01014962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral every 12 hours for 5 days
Trial: NCT01014962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral every 8 hours for 5 days
Trial: NCT02372591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Trial: NCT00793026
Drug: Dermacyd Breeze Pocket BR (Lactic Acid)
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days
Trial: NCT01360866
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT00099268
Drug: Carbidopa/levodopa/entacapone
RxNorm normalized name: carbidopa/levodopa/entacapone 25 mg-100 mg-200 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.
Trial: NCT02173652
Drug: BI 1356, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02173652
Drug: BI 1356, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03204071
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prophylaxis followed by Placebo gel to be delivered in intrabody sites of chronic periodontitis subjects.
Trial: NCT02973321
Drug: SAR425899
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered by SC injection using a solution for injection in cartridge.
Trial: NCT02973321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered by SC injection using a solution for injection in cartridge.
Trial: NCT06132620
Drug: Femoston
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenmorphone (this product is a compound preparation, estradiol tablets contain estradiol 2mg; Estradiol dydrogesterone tablets contain estradiol 2 mg and dydrogesterone 10 mg).~Usage: 1 time/day: 1 tablet orally every day, every 28 days as a course of treatment.
Trial: NCT06132620
Drug: Qingxin Zishen Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingxin Zi Kidney Decoction is a traditional Chinese medicine decoction, after regular decoction, 1 dose/day, divided into 2 doses.
Trial: NCT03177382
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive another 6 cycles of CAPOX after TME.
Trial: NCT02269644
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dalbavancin and linezolid randomized subjects on Day 1, 1st dose receive 500 mg of IV azithromycin
Trial: NCT02827890
Drug: Januvia Tab. 100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Januvia Tab. 100mg\*1T/day for 5days, QD, PO
Trial: NCT02827890
Drug: Januvia Tab. 100mg + Duvie Tab. 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Januvia Tab.100mg + Duvie Tab. 0.5mg\*1T/day for 5 dyas, QD, PO
Trial: NCT00004150
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004150
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01368926
Drug: RO4917523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral doses
Trial: NCT01368926
Drug: RO4917523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple oral doses
Trial: NCT01054352
Drug: JNJ38224342/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one of six (6) single ascending doses (25, 100, 300, 600, 1250 or 2000 mg) of JNJ 38224342 or matching placebo
Trial: NCT00865631
Drug: NEURONTIN® 400 mg capsules, single dose (2 capsules)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
Trial: NCT01017939
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline 100 mg tablets administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
Trial: NCT04659551
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamid 600 mg/mq i.v. every 3 weeks for three cycles
Trial: NCT03395639
Drug: Standard of Care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care could include low molecular weight heparin (LMWH) and/or VKA according to the clinical site's SOC treatment regimen
Trial: NCT02288208
Drug: Antiviral Therapy (tenofovir or entecavir)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02288208
Drug: Placebo (for birinapant)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02087176
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD 1775 + antimitotic agent+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
Trial: NCT02087176
Drug: AZD1775 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (to match dose) + antimitotic+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
Trial: NCT02087176
Drug: Antimitotic Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
Trial: NCT02155374
Drug: Intermediate acting insulin
RxNorm normalized name: Intermediate-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02155374
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician